Criminals Are Building Mansions Overseas

Honduras’ Siria Valley residents are using profits from drug sales in the San Francisco Bay Area to construct new houses and mansions by regional standards or by whatever-you-please standards, according to an article published by a San Francisco media outlet.

Since 2022, the study claims that over 200 Honduran migrants, including some illegal immigrants, have been prosecuted for drug selling. Most reside in the Siria Valley, and annual incomes range from $200,000 to $350,000.  A real estate explosion can be seen in the valley’s little towns thanks to the money being moved there. One dealer remarked on the impressiveness of his neighbors’ homes, citing one house in particular that he said had been constructed by a 17-year-old.

A convicted fentanyl dealer from Honduras told a local media source that residents of her Siria Valley love San Francisco. The report revealed that San Francisco’s position as a sanctuary city is a significant factor in this adoration. The local government has made it unlawful for ICE to deport illegal immigrants sentenced to time in city prisons.

Many major corporations have left San Francisco in recent years due to the city’s high crime rate, homelessness, and drug abuse epidemic.

The White House claims to have a strategy to reduce the distribution of a veterinary sedative that, when mixed with the already lethal fentanyl, increases the risk of fatal overdose. Officials in major California towns report an increase in the distribution of xylazine laced with fentanyl, a potent synthetic opioid medicine used to treat severe pain in hospitals. 

According to the California Department of Public Health, there were ten incidents of xylazine and fentanyl mixtures in Sacramento County in 2022.

According to federal authorities, Xylazine, often referred to as “tranq,” has been discovered in almost all 50 states. 

Human heart rate,  respiration, and blood pressure are dramatically slowed by tranq. Amputations may be necessary to treat abscesses that form at injection sites or elsewhere. 

The FDA has authorized the use of xylazine for sedation in several animal species. Its intended purpose never included humans.